Abstract Titles

Skip to Late-Breaking Abstracts »

All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).

Abstract Titles

Onsite Posters

Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.

ePosters

ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.


Search word or phrase:

# Type Title Authors Category Keywords
329 Poster Presentation Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of 4 multicenter clinical trials Jian-Guo Zhou, MD; Ada Hang-Heng Wong; Haitao Wang; Su-Han Jin; Fangya Tan; Yu-Zhong Chen; Si-si He; Gang Shen; Benjamin Frey; Markus Hecht; Rainer Fietkau; Bo Shen; Hu Ma; Udo S. Gaipl Clinical Trials Completed Bioinformatics;Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Epidemiology;Monocyte/Macrophage;Solid tumors
330 Poster Presentation Integration of molecular cancer classification and next-generation sequencing to identify metastatic patients eligible for immune checkpoint inhibitors Daruka Mahadevan; Li Ma, PhD; Kai Treuner, PhD; Jenna Wong, MS; Catherine A. Schnabel, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Gene expression;Solid tumors;Targeted therapy
331 Poster Presentation Tumor markers associated with increased survival in a phase II trial of dendritic cell/tumor-initiating-cell vaccine AV-GBM-1 in patients with newly diagnosed glioblastoma Daniela A. Bota, MD., PhD; David E. Piccioni, MD,PhD; Christopher M. Duma, MD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Jose A. Carrillo, MD; Frank Hsu, MD PhD; Xiao-Tang Kong, MD PhD; Mehrdad Abedi, MD; Robert D. Aiken, MD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD Clinical Trials Completed Biomarkers;Clinical trial;Dendritic cell;Neoantigens;Stem cell/cancer-initiating cell
332 Poster Presentation Tumor collection and establishment of tumor-initiating cell cultures as antigen source for AV-GBM-1 dendritic cell vaccines for a phase II trial in patients with newly diagnosed glioblastoma Christopher M. Duma, MD; Daniela A. Bota, MD., PhD; Frank Hsu, MD PhD; David E. Piccioni, MD,PhD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Mehrdad Abedi, MD; Jose A. Carrillo, MD; Robert D. Aiken, MD; Xiao-Tang Kong, MD PhD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD Clinical Trials Completed Clinical trial;Dendritic cell;Neoantigens;Stem cell/cancer-initiating cell;Vaccine
333 Poster Presentation Changes in proteomic markers after injections of personal AV-GBM-1 dendritic cell/tumor initiating cell vaccines in a phase II trial in patients with newly diagnosed glioblastoma Santosh Kesari, MD, PhD; Daniela A. Bota, MD., PhD; David E. Piccioni, MD PhD; Christopher M. Duma, MD; Renato V. LaRocca, MD; Xiao-Tang Kong, MD PhD; Frank Hsu, MD PhD; Jose A. Carrillo, MD; Mehrdad Abedi, MD; Robert D. Aiken, MD; Thomas H. Taylor, PhD; Aleksandra J. Poole, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD Clinical Trials Completed Clinical trial;Dendritic cell;Immune monitoring;Neoantigens;Proteomics;Vaccine
334 Poster Presentation Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with Tumor Treating Fields for newly diagnosed glioblastoma patients Adilia Hormigo, MD, PhD; Julia Kodysh, MSc; Cansu Cimen Bozkus, PhD; Mansi Saxena, PhD; Marcia Meseck, MS, JD; Alexander Rubinsteyn, PhD; Timothy J. O, PhD; Tin Htwe Thin, PhD; Rachel Brody, MD, PhD; John Mandeli, PhD; Nina Bhardwaj, MD, PhD Clinical Trials Completed Bioinformatics;Clinical study;Clinical trial;Immune monitoring;Immune suppression;Neoantigens;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
335 Poster Presentation Leukaphereses to obtain monocytes to produce dendritic cells in manufacturing of personal autologous AV-GBM-1 vaccines in a phase II trial in patients with newly diagnosed glioblastoma Renato V. LaRocca, MD; Daniela A. Bota, MD., PhD; David E. Piccione, MD, PhD; Christopher M. Duma, MD; Santosh Kesari, MD, PhD; Jose A. Carrillo, MD; Xiang-Tang Kong, MD PhD; Frank Hsu, MD PhD; Robert D. Aiken, MD; Mehrdad Abedi, MD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD Clinical Trials Completed Clinical trial;Dendritic cell;Monocyte/Macrophage;Neoantigens;Stem cell/cancer-initiating cell;Vaccine
336 Poster Presentation Adverse events in a phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens for patients with newly diagnosed glioblastoma David E. Piccioni, MD,PhD; Daniela A. Bota, MD., PhD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Jose A. Carillo, MD; Xiao-Tang Kong, MD, PhD; Christopher M. Duma, MD; Mehrdad Abedi, MD; Robert D. Aiken, MD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD Clinical Trials Completed Clinical trial;Dendritic cell;Immune toxicity;Stem cell/cancer-initiating cell;Vaccine
337 Oral Presentation Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic durvalumab Craig L. Slingluff, Jr., MD; Ileana S. Mauldin, PhD; Elizabeth M. Gaughan, MD; Patrick Dillon, MD; Mateusz Opyrchal, MD PhD; Igor Puzanov, MD, MSCI; Megan Kruse, MD; Brian Gastman, MD; Philip Friedlander, MD PhD; Thomas U. Marron, MD, PhD; Kristen Aufiero; Mary Macri, BSc; Paul Schwarzenberger, MD; Toni Ricciardi, BSMT; Aileen Ryan, MS; Ralph R. Venhaus, MD; Mansi Saxena, PhD; Nicole Edmonds; Nina Bhardwaj, MD, PhD Clinical Trials Completed Antibody;Checkpoint blockade;Clinical trial;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
338 Poster Presentation Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study Peter Schmid, MD, PhD; Yeon Hee Park; Eva Muñoz-Couselo; Sung-Bae Kim; Joohyuk Sohn; Seock-Ah Im; Esther Holgado; Theodoros Foukakis; Sherko Kümmel, MD, PhD; Rebecca Dent; Yuan Sun; Lingkang Huang, Ph.D.; Jennifer Yearley, PhD; Petar Jelinic, MD; Vassiliki Karantza; Javier Cortés Clinical Trials Completed Biomarkers;Checkpoint blockade;Gene expression;Tumor microenvironment;Tumor stroma
339 Poster Presentation Immune profiling to investigate improved survival in patients with metastatic triple-negative breast cancer receiving trilaciclib prior to chemotherapy Aaron D. Stevens; Joyce O'Shaughnessy; Subing Cao; Jessica Sorrentino; Janet Horton; John S. Yi; Antoinette R. Tan Clinical Trials Completed Chemotherapy;Clinical study;Gene expression;Immune monitoring;RNA;Solid tumors;T cell;T cell lineages;Tumor microenvironment
340 Poster Presentation A phase Ib study of the safety and tolerability of pixatimod plus nivolumab in subjects with advanced solid tumors with an expansion cohort in metastatic pancreatic adenocarcinoma (mPDAC) Charlotte Lemech, MBBS BSc(med) FRACP MD(res); Keith Dredge, PhD; Darryn Bampton; Edward Hammond; Amanda Stanley; Lucie Leveque-ElMouttie; Grace Chojnowski; Andrew M. Haydon, PhD; Nick Pavlakis; Matthew Burge; Michael P. Brown; David Goldstein Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors;T cell;TLR
341 Poster Presentation A phase Ib expansion cohort of pixatimod plus nivolumab in previously treated, microsatellite stable metastatic colorectal cancer (MSS mCRC). Charlotte Lemech, MBBS BSc(med) FRACP MD(res); Keith Dredge, PhD; Darryn Bampton; Edward Hammond; Andrew Clouson; Nigel Waterhouse; Amanda Stanley; Lucie Leveque-ElMouttie; Grace Chojnowski; Andrew M. Haydon, PhD; Nick Pavlakis; Matthew E. Burge; Michael P. Brown; david goldstein, MD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical trial;Dendritic cell;T cell;TLR;Tumor infiltrating lymphocytes (TILs)
342 Poster Presentation Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study David Krige, PhD; Marwan Fakih; Lee Rosen; Ding Wang, MD; Wael A. Harb, MD, CPI; Hani Babiker; Jordan Berlin, MD; Gianfranco Di Genova; David Miles; Mark Powell; Minesh Patel; Jo Carter; Richard A. Brown, PhD; Tom Lillie, MD PhD Clinical Trials Completed Checkpoint blockade;Clinical study;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
343 Poster Presentation Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer. Deena M. Maurer, PhD; Jia Xin Yu, PhD; Kamil Sklodowski, PhD; Marco Tognetti, PhD; Lukas Reiter, PhD; Roland Bruderer, PhD; Jakob Vowinckel, PhD; Shannon M. Pfeiffer, MS; Mark H. O'Hara, MD; Eileen M. O’Reilly, MD; Robert A. Wolff, MD; Zev A. Wainberg, MD; Andrew H. Ko, MD; Osama Rahm, MD; George A. Fisher, MD; Jaclyn P. Lyman, MS; Christopher R. Cabanski, PhD; Pier Federico Gherardini, PhD; Jill O’Donnell-Tormey, PhD; Theresa M. LaVallee, PhD; Robert H. Vonderheide, MD, PhD; Lacey J. Kitch, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Chemokine;Chemotherapy;Clinical trial;Costimulation;Immune suppression;Solid tumors
344 Poster Presentation Avelumab + binimetinib in metastatic pancreatic ductal adenocarcinoma (mPDAC): dose-escalation results from the phase 1b/2 JAVELIN PARP MEKi trial Jordi Rodon; Daniel S. Weng Tan; Ignacio Garrido Laguna; Wael Harb; J. Thaddeus Beck; Nathan Bahary, MD PhD; Sylvie Rottey, MD; Zhou Zhu; Shibing Deng; Karen Kowalski; Grainne O'Neill; Caimiao Wei; Nuzhat Pathan; Wells A. Messersmith, MD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy
345 Poster Presentation Phase I/II trial of cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies (CAMILLA): Phase Ib safety and efficacy results Anwaar Saeed, MD; Robin Park; Junqiang Dai; Raed Al-Rajabi; Anup Kasi; Joaquina Baranda; Stephen Williamson; Zachary Collins; Jacob Ripp; Azhar Saeed; Kelly Mulvaney; Vanna Manirad; Rashna Madan; Dharmalingam Subramaniam; Shrikant Anant; Milind Phadnis; Weijing Sun Clinical Trials Completed Angiogenesis;Checkpoint blockade;Clinical trial;Tumor microenvironment
346 Poster Presentation Translational program of the phase II MEDITREME trial: Identification of prognostic factors for response to durvalumab and tremelimumab in combination with FOLFOX in metastatic colorectal cancer. Marion Thibaudin, PhD; Elise Ballot; Emeric Limagne, PhD; Caroline Laheurte, PhD; Jean-David Fumet, MD; Caroline Truntzer, PhD; Olivier Adotevi, MD, PhD; François Ghiringhelli, MD, PhD Clinical Trials Completed Clinical trial;Immune monitoring;Neoantigens;T cell
347 Poster Presentation KEYNOTE-365 cohort C: Pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—Data after minimum of 22 months of follow-up Leonard J. Appleman, MD, PhD; Tilman Todenhoefer; William Berry; Howard Gurney; Margitta Retz; Henry Conter; Brigitte Laguerre; Peter Fong; Cristiano Ferrario; Gwenaelle Gravis; Josep M. Piulats, MD, PhD; Urban Emmenegger; Neal Shore, MD, FACS; Emanuela Romano, MD, PhD; Loic Mourey; Xin Tong Li; Christian H. Poehlein, MD; Charles Schloss; Johann S. De Bono, PhD; Evan Y. Yu, MD Clinical Trials Completed Checkpoint blockade;Clinical trial
348 Poster Presentation Interleukin 2(IL-2) Systems Immunology Modeling: Machine Learning for Cancer Immunotherapy Jennifer Bone, PhD; Newell R. Washburn, PhD; Jian Han, PhD; Miranda Steele; Pranav Murthy, BS; Michael T. Lotze, MD Clinical Trials Completed B cell;Bioinformatics;Immune monitoring;Systems biology;T cell
349 Poster Presentation Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3 Vijay Kasturi, MD; Bernard J. Escudier, MD; Brian I. Rini, MD; Sumanta K. Pal, MD; David F. McDermott, MD; Camillo Porta, MD; Elena Verzoni Clinical Trials Completed Checkpoint blockade;Clinical trial;Targeted therapy
350 Oral Presentation Phase 2 trial of a DNA vaccine with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) Douglas G. McNeel, MD, PhD; Jens Eickhoff, PhD; Ellen Wargowski, BS; Laura E. Johnson, PhD; Christos E. Kyriakopoulos, MD; Hamid Emamekhoo, MD; Joshua M. Lang, MD MS; Mary Jane Brennan, RN; Glenn Liu, MD Clinical Trials Completed Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Immune toxicity;Solid tumors;Tumor antigens;Vaccine
351 Poster Presentation KEYNOTE-365 cohort D: Pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) Josep M. Piulats, MD, PhD; Cristiano Ferrario; Mark Linch, MD; Michael Stoeckle; Brigitte Laguerre; Jose A. Arranz; Tilman Todenhoefer; Peter Fong; William Berry; Urban Emmenegger; Loic Mourey; Nataliya Mar, MD; Leonard J. Appleman, MD, PhD; Anthony M. Joshua, MBBS, PhD; Henry Conter; Xin Tong Li; Charles Schloss; Christian H. Poehlein, MD; Johann S. De Bono, PhD; Evan Y. Yu, MD Clinical Trials Completed Checkpoint blockade;Clinical trial
352 Poster Presentation Target Modulation within the Tumor Microenvironment (TME) by Daratumumab (anti-CD38) but not Edicotinib (CSF-1R inhibitor) in Men with High-Risk Localized Prostate Cancer Bilal A. Siddiqui, MD; Brian F. Chapin, MD; Sonali Jindal, MD; Fei Duan, PhD; Shalini Singh, PhD; Curtis A. Pettaway, MD; John F. Ward, III, MD; Rebecca S. Tidwell; Paul G. Corn, MD, PhD; Christopher J. Logothetis, MD; James P. Allison, PhD; Padmanee Sharma, MD, PhD; Sumit K. Subudhi, MD, PhD Clinical Trials Completed Clinical trial;Immune monitoring;Monocyte/Macrophage;Myeloid cells;Surgery;T cell;Tumor microenvironment
353 Poster Presentation Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer Oliver Dorigo, MD, PhD; Walead Ebrahimizadeh, PhD; Barry Kennedy, PhD; Lisa MacDonald, MSc; Stephan Fiset, MSc, MBA; Jeannine Villella, DO, FACOG, FACS; Amit OZA, MD; Tanja Pejovic, MD, PhD; Prafull Ghatage, MD, FRCSC; Sharad A. Ghamande, MD; Diane Provencher, MD FRCS FACOG; Yogesh Bramhecha, PhD Clinical Trials Completed Biomarkers;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
354 Poster Presentation Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study Vicky Makker, MD; Carol Aghajanian; Allen L. Cohn; Margarita Romeo; Raquel Bratos; Marcia S. Brose, MD PhD; Mark Messing; Lea Dutta; Corina E. Dutcus; Jie Huang; Emmett V. Schmidt, MD PhD; Robert J. Orlowski, MD; Matthew H. Taylor Clinical Trials Completed Angiogenesis;Antibody;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Targeted therapy
355 Poster Presentation Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients. Judith Michels, MD PhD; Jean-Sebastien Frenel; Catherine Genestie; François Ghiringhelli; Caroline Brard; Benoit You; Anne Floquet, MD; Lauriane Eberst; Rastilav BAHLEDA; Corinne Balleyguier; Angelo Paci; Joseph Ciccolini; Emeline Colomba; Fanny Pommeret; Christophe Massard, MD, PhD; Patricia Pautier, MD; Aurelien Marabelle; Alexandra Leary Clinical Trials Completed Angiogenesis;Checkpoint blockade;Clinical trial
356 Poster Presentation Personalized immunotherapy by adoptive T cell transfer during chemotherapy with or without interferon-alpha in patients with recurrent platinum-sensitive epithelial ovarian cancer Els M. Verdegaal, PhD; Marten Visser, MSc; Lien E. van der Minne, MSc; Linda de Bruin; Inge F. Roozen; Pauline Meij, PhD; Sjoerd H. van der Burg, Prof.Dr.; Judith R. Kroep, MD, PhD Clinical Trials Completed Adoptive immunotherapy;Chemotherapy;Clinical study;Clinical trial;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
357 Poster Presentation Toripalimab plus chemoradiotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II trial Xiaoting Xu; Jian Huan; Hui Miao; Hao Wang; Yue Wang; Hongyu Zhu; Jun Jiang; Juying Zhou, MD Clinical Trials Completed Antibody;Carcinogenesis;Chemotherapy;Clinical study;Clinical trial;Coinhibition;Genetic polymorphism;Immune contexture;Immune suppression;Solid tumors
358 Poster Presentation Ramucirumab in combination with pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma: A phase 1-2 trial Douglas R. Adkins, MD; Jessica Ley; Kevin Palka; Miriam T. Jacobs; Jingxia Liu, MS, PhD; Peter Oppelt, MD Clinical Trials Completed Angiogenesis;Checkpoint blockade;Clinical trial;Solid tumors
359 Poster Presentation Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC) Antonio López Pousa; Enriqueta Felip, MD, PhD; Martin Forster; Bernard Doger; Patricia Roxburgh; Pawan Bajaj; Julio A. Peguero, MD; Enric Carcereny, MD; Matthew G. Krebs, MD, PhD; Christian Mueller, MSc; Frederic Triebel, MD, PhD Clinical Trials Completed Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;T cell
360 Poster Presentation Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC) Chiun Hsu; Julien Edeline; Gianluca Masi; Yuk Ting Ma; Weilin Wang; Henning Wege; Cong Fei; Chen Ling; Xiaopeng Ma; Pei Zhang; Ruiqi Huang; Xikun Wu; Zhirong Shen; Bai Li; Sandra Chica Duque; Zhiqiang Meng Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical trial;Gene expression;Tumor microenvironment
361 Poster Presentation Heterogeneity of PD-1hi T cells associates with response to PD-1 blockade in hepatocellular carcinoma  Assaf Magen, PhD; Pauline Hamon, PhD; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Alice O. Kamphorst, PhD; Miriam Merad, MD, PhD Clinical Trials Completed Antigen presenting cells;Bioinformatics;Biomarkers;Checkpoint blockade;Costimulation;Immune monitoring;Immune suppression;Immunoscore;Tumor infiltrating lymphocytes (TILs);Tumor stroma
362 Poster Presentation Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma Philippe Merle; Helena Verdaguer Mata; Congying Xie; Richard Hubner; Yong Liu; Jane Margetts; Ying Cheng, MD; Yee Chao; Cong Fei; Chen Ling; Ruiqi Huang; Xikun Wu; Zhirong Shen; Bai Li; Sandra Chica Duque; Zhenggang Ren Clinical Trials Completed Biomarkers;Checkpoint blockade;Immune monitoring;Solid tumors
363 Poster Presentation KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer Gilberto De Castro, Jr., DR; Gilberto de Castro Jr, MD, PhD; Iveta Kudaba; Yi-Long Wu; Gilberto Lopes; Dariusz M. Kowalski; Hande Z. Turna; Christian Caglevic; Li Zhang; Boguslawa Karaszewska; Konstantin K. Laktionov; Vichien Srimuninnimit; Igor Bondarenko; Kaoru Kubota; Rinee Mukherjee; Jianxin Lin; Fabricio Souza; Tony S. K. Mok; Byoung Chul Cho, MD, PhD Clinical Trials Completed Antibody;Checkpoint blockade;Chemotherapy;Clinical trial;Solid tumors
364 Poster Presentation KRAS Mutations in Patients With Nonsquamous Non–Small-Cell Lung Cancer: Prevalence and Relationship With PD-L1 Expression, Tumor Mutation Burden and Smoking Status Marina Chiara Garassino, MD; Marina C. Garassino; Delvys Rodriguez-Abreu; Shirish M. Gadgeel; Dariusz M. Kowalski; Kazuo Kasahara; Enriqueta Felip, MD, PhD; Yi-Long Wu; Gilberto de Castro Jr, MD, PhD; Byoung Chul Cho, MD, PhD; Hande Z. Turna; Hidehito Horinouchi; Martin Reck; Rina Hui; Edward B. Garon; Michael Boyer, MB BS PhD; Tony S.K. Mok; Gilberto Lopes; Julie Kobie; Yongjin Li; Mark A. Ayers; Razvan Cristescu; Bin Zhao; M. Catherine Pietanza; Roy S. Herbst Clinical Trials Completed Biomarkers;Checkpoint blockade;Chemotherapy;Clinical trial;Gene expression;Targeted therapy
365 Poster Presentation Computational pathology delivers objective and quantitative PD-L1 expression analysis for enrichment of responders to durvalumab in non-small cell lung cancer (NSCLC) Guenter Schmidt, PhD; Ansh Kapil; Lina Meinecke, PhD; Farzad Sekhavati, PhD; Jan Lesniak, PhD; Anatoliy Shumilov, PhD; Thomas Padel, PhD Clinical Trials Completed Bioinformatics;Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors
366 Poster Presentation Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial Santiago Viteri, MD; Werner Hilgers; Fabrice Denis; Elisabeth Quoix, MD; Gilles Robinet, MD; Enriqueta Felip, MD, PhD; Rafal Dziadziuszko, MD; Nicolas Poirier; Claudia Fromond, PhD; Isabelle Girault; Thomas Vandewalle; Dominique Costantini, MD; Bérangère Vasseur, MD; Federico Cappuzzo, MD; Giuseppe Giaccone, MD; Benjamin Besse, MD, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Immunoscore;Solid tumors;Tumor antigens;Tumor microenvironment;Vaccine
367 Poster Presentation Pharmacokinetic and immunologic data from a Phase I study of the click chemistry-based therapy SQ3370 in advanced solid tumors and soft-tissue sarcoma provides proof-of-concept for the CAPAC platform Vivek A. Bhadri, MD, PhD; Vivek Subbiah, MD; James F. Strauss, MD; Sant P. Chawla, MD; Nam Bui, MD; Vineet Kwatra, MD; Mia Weiss, MD; Kathleen Batty, MD; Michael Zakharian, MS; Jose M. Mejia Oneto, MD, PhD; Sangeetha Srinivasan, PhD; Nathan A. Yee, PhD; Rosalind Wilson, MD; M. Wayne Saville, MD; Alexander Guminski, MD, PhD Clinical Trials Completed Antigen presenting cells;Clinical study;Clinical trial;Immune adjuvant;Immune suppression;Inflammation;Tumor antigens;Tumor stroma
368 Poster Presentation Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors Lukasz Kuryk, PhD; Anne-Sophie Moller; Sandeep Kumar; Alexander N. Shoushtari, MD; Luis Paz Ares, MD, PhD; Magnus Jaderberg; Erik Digman Wiklund, PhD; Victor Levitsky, MD, PhD Clinical Trials Completed Checkpoint blockade;Chemotherapy;Gene expression;Immune monitoring;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
369 Poster Presentation Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers Devalingam Mahalingam, MBBCh BAO; Mary Mulcahy, MD; Dejan Juric; Manish R. Patel, MD; Shubham Pant, MD; Susanna Ulahannan, MD, MMED; Afshin Dowlati; Andrea J. Bullock, MD; Lou Vaickus, MD; Susanne Fyfe; Melanie Vincent, PhD; Suming Wang, Ph.D; Jian J. Chen, PhD; Marsha Crochiere, PhD; Randolph Watnick, Ph.D; Michael Cieslewicz, Ph.D; Jing Watnick, Ph.D Clinical Trials Completed Biomarkers;Clinical study;Clinical trial;MDSC;Solid tumors;Tumor microenvironment
370 Poster Presentation Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial Bhavana Pothuri, MD; Dominique Berton, MD; Victor Moreno; Ana Oaknin, MD; Jose Manuel Trigo Perez, MD, PhD; Giuseppe Curigliano, MD, PhD; Susan Ellard; Joanna Pikiel, Dr n. med.; Susana Banerjee; Maria-Pilar Barretina-Ginesta; Rowan Miller; Anna Tinker; Andrea Jewell; Ruth Plummer; Florence Joly; Jennifer Veneris; Tao Duan; Thierry Andre, MD PhD Clinical Trials Completed Clinical trial;Solid tumors
371 Poster Presentation Analysis of changes in plasma cytokine levels in response to IL-12 therapy in three clinical trials Emily Schwarz, BS; Brooke Benner, PhD; Lianbo Yu, PhD; William E. Carson, III, MD, FACS Clinical Trials Completed Chemokine;Clinical study;Clinical trial;Cytokine;Immune monitoring;Myeloid cells;NK/NKT cell;T cell
372 Poster Presentation Association of tumor mutation burden (TMB) and genomic alterations (GA) with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab Lin Shen; Qingyuan Zhang; Tianshu Liu; Hongming Pan; Yuxian Bai; Ying Yuan; Xuerui Luo; Yang Shi; Yun Zhang; Ruiqi Huang; Juan Zhang; Zhirong Shen Clinical Trials Completed Biomarkers;Checkpoint blockade;Solid tumors
373 Poster Presentation Enhancement of TCR-engineered T-cells targeting MAGE-A4 antigen by co-expression of CD8α and inhibition of AKT signaling during ex vivo T-cell expansion Emily Schmidt, PhD; Katerina Mardilovich, PhD; Natalie Bath, MSc; Gareth Betts, PhD; William Spinner; Kathryn Sun; Ian Donaldson; Cheryl McAlpine; Raymond Luke; Jean-Marc Navenot; Joseph P. Sanderson, PhD; Phil Bassett; Chris Evans; Karen Miller, PhD; Quan Lin; Mark Dudley; Alex J. Tipping, PhD Clinical Trials Completed T cell
374 Oral Presentation A Phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors Kevin Tyan, BA; Osama E. Rahma, MD; Anita Giobbie-Hurder, MS; Andrew S. Brohl, MD; Philippe Bedard, MD; Daniel Renouf, MD; Elad Sharon, MD, MPH; Howard Streicher, MD; Emma Hathaway; Rachel Cunningham; Michael P. Manos; Mariano Severgnini, MSc; Scott J. Rodig, MD, PhD; F. Stephen Hodi, Jr., MD Clinical Trials Completed Angiogenesis;Biomarkers;Checkpoint blockade;Chemokine;Clinical study;Clinical trial;Solid tumors;T cell;T cell lineages;Tumor microenvironment
375 Poster Presentation Development of Thrombospondin-1 as a clinical pharmacodynamic biomarker for VT1021, a first-in-class therapeutic agent that reprograms the tumor microenvironment. Jian J. Chen, PhD; Marsha Crochiere, PhD; Melanie Vincent, PhD; Suming Wang, Ph.D; Susanne Fyfe; Wendy Li; Simai Deng; Randolph Watnick, Ph.D; Jing Watnick, Ph.D; Michael Cieslewicz, Ph.D Clinical Trials Completed Biomarkers;Clinical study;Clinical trial;MDSC;Solid tumors;Tumor microenvironment
376 Poster Presentation Radiation sub-study to characterize safety and tolerability of low-dose radiation in combination with afami-cel in patients with advanced cancers (NCT03132922) James Welsh; Danxia Ke; Nahum Puebla Osorio; Hampartsoum Barsoumian; Bryan Jackson; Jane Bai; Marisa B. Rosenberg, MS; Cheryl McAlpine; Robyn Broad; Ashley Liddle; Jean-Marc Navenot; Stavros Rafail; Ruoxi Wang; Amy Sauer; Quan Lin; Hassan Danesi; David S. Hong, Professor Clinical Trials Completed T cell
377 Poster Presentation Characterization of peripheral biomarkers of GS-1423, a first in class bifunctional anti-CD73-TGFβ receptor II- trap molecule, in a Phase 1 dose escalation study in patients with advanced solid tumors Marianna Zavodovskaya, M.S.; Anthony Tolcher, M.D., FRCPC, FACP; Michael Gordon, MD; James F. Strauss, MD; Kathleen Mahoney, MD, PhD; Ping Cheng Yi, M.S.; Rick Sorensen, BS; Xiaoyun Yang, PhD; Kai-Wen Lin; Biao Li, PhD; Anna Seto, PharmD; Matthew L. Peach, MS; Audrey D. Goddard, Ph.D.; Tianling Chen, MD, MSc; Juliane M. Jürgensmeier, PhD Clinical Trials Completed Antibody;Biomarkers;Bispecifics;Clinical trial;Solid tumors;Tumor microenvironment
378 Poster Presentation Efficacy, Safety and Ancillary analyses of Pembrolizumab in combination with Nintedanib for the treatment of Patients with relapsed Advanced Mesothelioma. Francois-Xavier Danlos, MD, PhD student; Capucine Baldini, MD; Matthieu Texier; Andreea Varga, MD; Séverine Mouraud, MS; Bastien Job; Diane Letourneur; Lydie Cassard, PhD; Delphine Bredel; Salim Laghouati; Julien Adam, MD; Nathalie Droin, PhD; Aurelien Parpaleix; Nathalie Chaput-Gras; Audrey Rabeau, MD; Gerard Zalcman; David Planchard, MD, PhD; Christophe Massard, MD, PhD; Jean-Charles Soria, MD, PhD; Aurelien Marabelle Clinical Trials Completed Angiogenesis;Biomarkers;Checkpoint blockade;Chemokine;Clinical study;Clinical trial;Immune monitoring;Inflammation;Solid tumors;Tumor microenvironment
379 Oral Presentation Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma (STS) treated with neoadjuvant immune checkpoint blockade (ICB) Emily Z. Keung, MD, MA; Elise F. Nassif; Heather Lin, PhD; Alexander J. Lazar, MD / PhD; Wei-Lien Wang; Edwin R. Parra, MD, PhD; Cibelle F. Lima; Ignacio Wistuba, MD; Ashleigh Guadagnolo; Andrew J. Bishop; Valerae O. Lewis; Keila Torres; Kelly K. Hunt, MD; Barry W. Feig; Christopher P. Scally; Ahmed N. Al Rawi; Shadarra D. Crosby; Grace Mathew; Davis Ingram; Khalida Wani, PhD; Jennifer A. Wargo, MD, MMSc; Neeta Somaiah, MD, MBBS; Christina L. Roland, MD, MS, FACS Clinical Trials Completed B cell;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Regulatory T cell (Treg cell);Surgery;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
380 Poster Presentation GS-3583, a novel FLT3 agonist Fc fusion protein, expands conventional dendritic cells in healthy volunteers Nishanthan Rajakumaraswamy, MD; Anees Dauki; Michelle R. Kuhne, PhD; Torsten Trowe; Winnie Weng; Kai-Wen Lin; Emon Elboudjwarej; Brian Carr; Angela Worth; Anshu Vashishtha; Christian Schwabe; Ahmed A. Othman Clinical Trials Completed Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune monitoring;Solid tumors;Tumor antigens;Tumor microenvironment
381 Poster Presentation Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: The phase 1b MITCI study Carlo D. Bifulco, MD; Jon Richards; John Hyngstrom, MD; Gregory Daniels; Mark B. Faries, MD; Lynn Feun; Kim Margolin; Sigrun Hallmeyer; Mark Grose; Yiwei Zhang; Anlong Li; Robert H. I. Andtbacka Clinical Trials Completed Checkpoint blockade;Clinical trial;Immune toxicity;Vaccine
382 Poster Presentation The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanoma Espen B. Ellingsen, MD; Iliana Kerzeli; Irantzu Anzar; Nadia Mensali, PhD; Trevor Clancy; Sara M. Mangsbo, PhD MSc; Steinar Aamdal; Elin Aamdal; Tormod K. Guren, MD, PhD; Else-Marit Inderberg-Suso; Eivind Hovig; Gustav Gaudernack Clinical Trials Completed Checkpoint blockade;Clinical trial;Gene expression;Immune monitoring;RNA;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
383 Poster Presentation Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from Keynote 695 Pablo Fernandez-Penas, MD, PhD; Matteo S. Carlino, M.D., Ph.D.; Katy K. Tsai, MD; Victoria G. Atkinson, MD; Monaster Shaheen; Sajeve S. Thomas; Catalin Mihalcioiu, MD, FRCP; Tom Van Hagen, MD; Rachel Roberts-Thomson, MD; Andrew M. Haydon, PhD; Andrew Mant, MD; Marcus O. Butler; Gregory Daniels; Elizabeth Bunchbinder; John Hyngstrom, MD; Mecker Moller; Igor Puzanov, MD, MSCI; C Lance Cowey; Eric D. Whitman, MD, FACS; Carmen Ballesteros-Merino, PhD; Shawn Jensen, PhD; Bernard Fox, PhD; Emmett V. Schmidt, MD PhD; Scott J. Diede, MD, PhD; Rebecca Setta; Jendy Sell; David Canton; Sandra Aung; Christopher Twitty; Sunny Xie; Ying Lu; Bridget O'Keefe; Alain P. Algazi, MD; Adil I. Daud, MD Clinical Trials Completed Checkpoint blockade;Clinical trial;Cytokine;Solid tumors;Tumor microenvironment
384 Poster Presentation An investigation into the role of CD4+ tumor-infiltrating lymphocytes (TIL) in metastatic melanoma patients with a complete response to adoptive cell therapy MacLean Hall, BS; Holly Branthoover; Patrick Innamarato, B.S.; Amy M. Hall; Alex Alfaro; Allison Richards; Jeani Rich; Jonathan A. Hensel, PhD; Jim Bender; Jake Ceccarelli; TJ Langer; Matthew Beatty, PhD; John E. Mullinax, MD; Jamie Teer, PhD; Amod A. Sarnaik; Shari A. Pilon-Thomas, PhD Clinical Trials Completed Adoptive immunotherapy;Neoantigens;T cell;Tumor infiltrating lymphocytes (TILs)
385 Poster Presentation Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL) MacLean Hall, BS; Holly Branthoover; Matthew Beatty, PhD; Kwame Twumasi-Boateng; Jim Bender; Jake Ceccarelli; TJ Langer; Jamie Teer, PhD; Amod A. Sarnaik; Shari A. Pilon-Thomas, PhD Clinical Trials Completed Adoptive immunotherapy;Neoantigens;T cell;Tumor infiltrating lymphocytes (TILs)
387 Poster Presentation The utility of AI-powered spatial classification of intratumoral CD8+ immune-cell distribution in predicting overall survival in patients with melanoma as part of the CheckMate 067 clinical trial George Lee, PhD; Keyur Desai, PhD; Hao Tang, PhD; Daniel N. Cohen, MD, PhD; Scott Ely; John B. Wojcik, MD, PhD; Jimena Trillo-Tinoco; Benjamin J. Chen, MD, PhD; Akshita Gupta; Daniel Tenney; Vipul Baxi, MS; Robin Edwards, MD; Megan Wind-Rotolo, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune suppression;Solid tumors;T cell;Tumor evasion;Tumor microenvironment;Tumor stroma
388 Poster Presentation A trial to evaluate the safety, immunogenicity, and clinical activity of a helper peptide vaccine plus PD-1 blockade (Mel64, PATHVACS: PD-1 antibody and T-helper vaccine and correlative studies) Craig L. Slingluff, Jr., MD; Kimberly A. Chianese-Bullock, PhD; Ileana S. Mauldin, PhD; Walter C. Olson, Jr., PhD; Kelly Smith; Lynn T. Dengel, MD; Kathleen Haden, NP, MS; Elizabeth M. Gaughan, MD; Varinder Kaur, MD; William W. Grosh, MD Clinical Trials Completed Antibody;Checkpoint blockade;Clinical trial;Immune adjuvant;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
389 Poster Presentation Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy Sarah A. Weiss, MD; Mario Sznol, MD; Montaser Shaheen, MD; Miguel-Ángel Berciano-Guerrero, MD, PhD; Enriqueta Felip, MD, PhD; Delvys Rodríguez-Abreu, MD; Ana Maria Arance, MD, PhD; Valentina Boni, MD, PhD; Gerald P. Linette, MD, PhD; Lynn M. Schuchter, MD; Maria Gonzalez-Cao, MD, PhD; Nicholas O. Iannotti, MD; Apar Kishor Ganti, MD, MS; Ralph J. Hauke, MD; Alfonso Berrocal, MD; Erin L. Filbert, PhD; Harriet M. Kluger, MD Clinical Trials Completed Antibody;Antigen presenting cells;Clinical trial;Costimulation;Solid tumors